LTO1 as A Potential Drug Target Or Biomarker for Oral Cancer (G220064)

Target Name: LTO1

NCBI ID: G220064

LTO1

LTO1 as A Potential Drug Target Or Biomarker for Oral Cancer

LTO1 (Oral cancer overexpressed protein 1-A) is a protein that is expressed in the tongue and mouth, and is often used as a biomarker for oral cancer. It is a member of the evolutionarily conserved superfamily of cytoplasmic organizing regions (SOCRs), which are involved in the regulation of cell growth, differentiation, and survival.

Recent studies have suggested that LTO1 may be a potential drug target for oral cancer. One reason for this is that LTO1 has been shown to be overexpressed in a variety of oral cancer tissues, including those from the most aggressive forms of the disease. This suggests that targeting LTO1 may be a way to inhibit the growth and progression of these tumors.

Another potential mechanism by which LTO1 may be involved in oral cancer is its role in cell signaling. LTO1 has been shown to be involved in a variety of signaling pathways, including those that regulate cell adhesion, migration, and invasion. It is also known to play a role in the regulation of angiogenesis, the formation of new blood vessels that can supply tumors with the oxygen and nutrients they need to grow.

In addition to its potential role in cell signaling, LTO1 is also of interest as a potential biomarker for oral cancer. This is because it is often overexpressed in oral cancer tissues, and can be used as a marker for the disease. This is important because it allows researchers to study the effects of different treatments on LTO1 levels, which can provide valuable information about the effectiveness of these treatments.

Targeting LTO1 may also be a way to identify new potential drug targets for oral cancer. By studying the role of LTO1 in cell signaling and cancer growth, researchers may be able to identify new targets for drugs that can inhibit its activity. This could lead to the development of more effective and targeted treatments for this difficult-to-treat form of cancer.

Overall, LTO1 is a protein that has the potential to be a drug target or biomarker for oral cancer. Its involvement in cell signaling and its potential as a biomarker make it an attractive target for researchers to study. Further studies are needed to fully understand its role in cancer and to identify its potential as a drug target.

Protein Name: LTO1 Maturation Factor Of ABCE1

Functions: The complex LTO1:YAE1 functions as a target specific adapter that probably recruits apo-ABCE1 to the cytosolic iron-sulfur protein assembly (CIA) complex machinery (PubMed:26182403). May be required for biogenesis of the large ribosomal subunit and initiation of translation (PubMed:23318452). May play a role in the regulation of proline metabolism and ROS production (PubMed:24930674)

The "LTO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets